Publications

ProMab's goal to become one of the leading providers in CAR-T research & immunotherapy space allows us to post our findings on accredited research publications.

Hypoxia Selectively Impairs CAR-T Cells In Vitro.

Berahovich R, Liu X, Zhou H, Tsadik E, Xu S, Golubovskaya V, Wu L.
> View Article
 

Generation of CAR-T Cells for Cancer Immunotherapy.

Xu Q, Harto H, Berahovich R, Xu S, Zhou H, Golubovskaya V, Wu L.
> View Article
 

CAR-T Cells Based on Novel BCMA Monoclonal Antibody Block Multiple Myeloma Cell Growth.

Berahovich R, Zhou H, Xu S, Wei Y, Guan J, Guan J, Harto H, Fu S, Yang K, Zhu S, Li L, Wu L, Golubovskaya V.
> View Article
 

GITR domain inside CAR co-stimulates activity of CAR-T cells against cancer.

Golubovskaya VM, Berahovich R, Xu Q, Zhou H, Xu S, Guan J, Harto H, Li L, Wu L.
> View Article
 

CAR-T Cell Therapy: From the Bench to the Bedside.

Golubovskaya V.
> View Article
 

CD47-CAR-T Cells Effectively Kill Target Cancer Cells and Block Pancreatic Tumor Growth.

Golubovskaya V, Berahovich R, Zhou H, Xu S, Harto H, Li L, Chao CC, Mao MM, Wu L.
> View Article
 

FLAG-tagged CD19-specific CAR-T cells eliminate CD19-bearing solid tumor cells in vitro and in vivo.

Berahovich R, Xu S, Zhou H, Harto H, Xu Q, Garcia A, Liu F, Golubovskaya VM, Wu L.
> View Article
 

Major Highlights of the CAR-TCR Summit, Boston, 2016.

Golubovskaya V, Berahovich R, Xu S, Harto H, Wu L.
> View Article
 

Different Subsets of T Cells, Memory, Effector Functions, and CAR-T Immunotherapy.

Golubovskaya V, Wu L.
> View Article
 

Transferrin epitope-CD19-CAR-T cells effectively kill lymphoma cells in vitro and in vivo.

Valentine M., Le Li,, Hua Zhou, Shirley Xu, Jinying Sun, Chengjing Liu, Hizkia Harto, Robert Berahovich, Vita Golubovskaya, Lijun Wu,
> View Article